Dr. Reddy's Laboratories announces the launch of Raloxifene HCl Tablets, USP in the U.S. Market

Hyderabad, India, 11 November 2016                                                                                                       

Hyderabad, India and Princeton, NJ, USA. 11 November 2016 - Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista^®(raloxifene hydrochloride) tablets in the United States market, approved by the U.S. Food & Drug Administration (USFDA).

The Evista^® brand and generic had U.S. sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health*.

Dr. Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.

Evista^® is a registered trademark of Eli Lilly and Company.

*IMS National Sales Perspective: Retail and Non-Retail MAT September 2016

RDY-1016-134